ArticleMolecular oncology2026

Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.

Ulrik Ringborg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.